Biovest to spin off instrument and contract manufacturing business


New subsidiary will be called Cell Culture Company

US biotechnology firm Biovest is to spin off its instrument and contract manufacturing business into a single wholly-owned subsidiary.

Called Cell Culture Company, the firm will supply automated single-use perfusion bioreactor systems and custom mammalian cell and protein manufacturing services to the diagnostic, therapeutic, and animal healthcare industries.

Since the late 1990s, Biovest’s primary focus has been the commercialisation of personalised immunotherapies and that work will continue under the Biovest name.

Cell Culture Company President Christiaan Engstrom said the spin-off 'will ensure that our instrument and CMO customers will be better served through increased focus and investment'.

For more than 30 years, Biovest has been delivering innovative, cost effective, and scalable GMP custom mammalian cell and protein production and services solutions, from pre-clinical to commercial stages in mg to kg quantities.

Sign up for your free email newsletter

'It is our goal to be recognised as a preferred partner and industry leader in bioreactor technology and cell culture services,' Engstrom added. Cell Culture Company will remain in the Minneapolis, Minnesota area, in the same facility it has occupied since the 1980s. The 33,000ft2 location is home to the corporate offices, bioreactor manufacturing operations, and a distribution centre, as well as an FDA-compliant custom mammalian and protein production laboratory.